Treatment efficacy and safety of drug-eluting beads transarterial chemoembolization versus conventional transarterial chemoembolization in hepatocellular carcinoma patients with arterioportal fistula

References

• Llovet JM, Zucman-Rossi J, Pikarsky E, Sangro B, Schwartz M, Sherman M, Gores G. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18.
   PubMed Web of Science ®Google Scholar
• Kulik L, El-Serag HB. Epidemiology and Management of Hepatocellular Carcinoma. Gastroenterology. 2019;156(2):477–91 e1. doi:10.1053/j.gastro.2018.08.065.
   PubMed Web of Science ®Google Scholar
• de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology. 2015;62(4):1190–1200. doi:10.1002/hep.27969.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng AL, Kokudo N, Kudo M, Lee JM, Jia J, Tateishi R, Han K-H, Chawla YK, Shiina S, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11(4):317–370. doi:10.1007/s12072-017-9799-9.
   PubMed Web of Science ®Google Scholar
• Lanza E, Donadon M, Poretti D, Pedicini V, Tramarin M, Roncalli M, Rhee H, Park YN, Torzilli G. Transarterial Therapies for Hepatocellular Carcinoma. Liver Cancer. 2016;6(1):27–33. doi:10.1159/000449347.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence. Cancer Treat Rev. 2019;72:28–36. doi:10.1016/j.ctrv.2018.11.002.
   PubMed Web of Science ®Google Scholar
• Sieghart W, Hucke F, Peck-Radosavljevic M. Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol. 2015;62(5):1187–1195. doi:10.1016/j.jhep.2015.02.010.
   PubMed Web of Science ®Google Scholar
• Bruix J, Han KH, Gores G, Llovet JM, Mazzaferro V. Liver cancer: approaching a personalized care. J Hepatol. 2015;62(1):S144–56. doi:10.1016/j.jhep.2015.02.007.
   PubMedGoogle Scholar
• Choi JW, Lee JM, Kim HC, Lee M, Hur S, Jae HJ, Chung JW. Iatrogenic Arterioportal Fistula Caused by Radiofrequency Ablation of Hepatocellular Carcinoma: clinical Course and Treatment Outcomes. J Vasc Interv Radiol. 2020;31(5):728–736. doi:10.1016/j.jvir.2019.10.020.
   PubMed Web of Science ®Google Scholar
• Luo MY, Shan H, Jiang ZB, Liang WW, Zhang JS, Li LF. Capability of multidetector CT to diagnose hepatocellular carcinoma-associated arterioportal shunt. World J Gastroenterol. 2005;11(17):2666–2669. doi:10.3748/wjg.v11.i17.2666.
   PubMed Web of Science ®Google Scholar
• Liu QS, Mei QL, Li YH. Polyvinyl alcohol terminal chemoembolization for hepatocellular carcinoma with hepatic arteriovenous shunts: safety, efficacy, and prognostic factors. Eur J Radiol. 2017;89:277–283. doi:10.1016/j.ejrad.2016.04.016.
   PubMed Web of Science ®Google Scholar
• Shi HB, Yang ZQ, Liu S, Zhou WZ, Zhou CG, Zhao LB, Xia J-G, Li L-S. Transarterial embolization with cyanoacrylate for severe arterioportal shunt complicated by hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36(2):412–421. doi:10.1007/s00270-012-0410-4.
   PubMed Web of Science ®Google Scholar
• Melchiorre F, Patella F, Pescatori L, Pesapane F, Fumarola E, Biondetti P, Brambillasca P, Monaco C, Ierardi AM, Franceschelli G, et al. DEB-TACE: a standard review. Future Oncol. 2018;14(28):2969–2984. doi:10.2217/fon-2018-0136.
   PubMed Web of Science ®Google Scholar
• Zhu D, Yuan D, Wang Z, Chen S. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients. Medicine (Baltimore). 2019;98(26):e15682. doi:10.1097/MD.0000000000015682.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhou J, Zhu DD, Huang J, Sun JH, Li TF, Shi C-S, Sun Z-C, Hou Q-M, Peng Z-Y, et al. CalliSpheres(R) drug-eluting beads (DEB) transarterial chemoembolization (TACE) is equally efficient and safe in liver cancer patients with different times of previous conventional TACE treatments: a result from CTILC study. Clin Transl Oncol. 2019;21(2):167–177. doi:10.1007/s12094-018-1902-8.
   PubMed Web of Science ®Google Scholar
• Zou JH, Zhang L, Ren ZG, Ye SL. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016;17(8):510–517. doi:10.1111/1751-2980.12380.
   PubMed Web of Science ®Google Scholar
• Luz JH, Luz PM, Martin HS, Gouveia HR, Levigard RB, Nogueira FD, Rodrigues BC, de Miranda TN, Mamede MH. DEB TACE for Intermediate and advanced HCC - Initial Experience in a Brazilian Cancer Center. Cancer Imaging. 2017;17(1):5. doi:10.1186/s40644-017-0108-6.
   PubMedGoogle Scholar
• Xiao YD, Ma C, Zhang ZS, Liu J. Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience. Cancer Manag Res. 2019;11:1551–1557. doi:10.2147/CMAR.S193948.
   PubMed Web of Science ®Google Scholar
• Liang B, Xiang H, Ma C, Xiong B, Ma Y, Zhao C, et al. Comparison of chemoembolization with CalliSpheres((R)) microspheres and conventional chemoembolization in the treatment of hepatocellular carcinoma: a multicenter retrospective study. Cancer Manag Res. 2020;12:941–956. doi:10.2147/CMAR.S187203.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Bellanti F, Villani R, Salvatore V, Muscatiello N, Piscaglia F, et al. Transarterial chemoembolization vs bland embolization in hepatocellular carcinoma: a meta-analysis of randomized trials. United European Gastroenterol J. 2017;5(4):511–518. doi:10.1177/2050640616673516.
   PubMed Web of Science ®Google Scholar
• Golfieri R, Giampalma E, Renzulli M, Cioni R, Bargellini I, Bartolozzi C, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111(2):255–264. doi:10.1038/bjc.2014.199.
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52. doi:10.1007/s00270-009-9711-7.
   PubMed Web of Science ®Google Scholar
• Liang B, Makamure J, Shu S, Zhang L, Sun T, Zheng C. Treatment Response, Survival, and Safety of Transarterial Chemoembolization With CalliSpheres((R)) Microspheres Versus Conventional Transarterial Chemoembolization in Hepatocellular Carcinoma: a Meta-Analysis. Front Oncol. 2021;11:576232. doi:10.3389/fonc.2021.576232.
   PubMed Web of Science ®Google Scholar